CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017. Pacritinib Drug developed by S*BIO, EDBI Portfolio Company
SEATTLE, Jan. 9, 2017 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced positive progress on its lead programs in addition to key business priorities for 2017.